ArticleApplied microbiology and biotechnology2026
Development and analytical validation of a dual-gene isothermal assay for Nipah virus detection.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessing the pandemic potential of Nipah virus: From molecular pathogenesis to ecological spillover risks.Infectious medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV) is a highly pathogenic zoonotic virus characterized by fatal encephalitis and severe respiratory illness, with case-fatality rates reaching 75%. Given the lack of licensed vaccines or therapeutics, rapid and accurate detection is paramount for outbreak containment. While real-time reverse transcription polymerase chain reaction (qRT-PCR) remains the gold standard, its requirement for sophisticated laboratory infrastructure limits its utility in resource-constrained field settings. In this study, we developed and validated a rapid, colorimetric dual-target reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay targeting the conserved matrix and nucleocapsid genes to enhance diagnostic reliability. Optimized at 62 °C for 40 min, the assay provides a clear visual colorimetric interpretation. A total of 137 samples were evaluated: in vitro-transcribed (IVT) RNA and tissue culture fluid isolate dilutions for limit of detection assessment, 57 non-NiV viral samples for cross-reactivity assessment, and 10 experimentally spiked positive clinical matrices used as proxy clinical specimens together with 50 confirmed NiV-negative clinical swabs for preliminary proxy diagnostic performance evaluation. The dual-target assay demonstrated 100% analytical sensitivity (95% confidence interval or CI, 72.2-100.0) and 100% specificity (95% CI, 92.9-100.0), showing perfect agreement (κ = 1.00) with real-time reverse transcription polymerase chain reaction (qRT-PCR). The composite "matrix or nucleocapsid" interpretation rule supported complete detection in the tested proxy positive clinical-matrix specimens. This simple, cost-effective, and portable molecular tool is well-suited for decentralized diagnostics, supporting early detection and surveillance in NiV-endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.